panacos pharmaceuticals inc
(PANC:OTC US)

Executive Profile*

Background*

Dr. Alan W. Dunton, M.D. has been Consulting Chief Medical Officer of Marina Biotech, Inc. since September 1, 2011. Dr. Dunton founded Danerius, LLC in 2006 and serves as its Principal Owner. Dr. Dunton served as the Chief Executive Officer of Panacos Pharmaceuticals Inc. from January 8, 2007 to March 2009 and President from July 31, 2007 to March 2009. At Panacos, he guided an HIV product into late-stage clinical development and its subsequent sale. He serves as Consultant ... of Davierius LLC. He has 23 years of experience in clinical research, drug development, and the regulatory process, highlighted by leadership roles in the development and approval of the prescription drugs Levaquin®, TOPAMAX®, Reminyl®, Regranex®, and Risperdal®, as well as the successful OTC product Aleve®. Dr. Dunton served as the Chief Executive Officer and President of MetaPhore Pharmaceuticals Inc., from February 2003 to December 2005. He served as the President of Emisphere Technologies Inc. from January 2002 to December 2002 and also served as its Chief Executive Officer. He served as the President and Managing Director of Janssen Research Foundation, a subsidiary of Johnson & Johnson from October 1996 to December 2001 and served in Executive positions at Hoffmann La Roche Inc., CIBA-GEIGY (now Novartis), and Syntex Corporation. He served as Group Vice President for Development at R.W. Johnson Pharmaceutical Research Institute. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. He served as Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. From 1994 to 2002, Dr. Dunton served as a Senior Executive in various capacities within the Pharmaceuticals Group of Johnson & Johnson, where he was responsible for the development and regulatory activities for such blockbuster drugs as Levaquin(R), Topamax(R) and Risperdal(R) line extensions. Earlier in his career he served clinical research and clinical pharmacology positions at Syntex Corporation, Ciba-Geigy Corporation, Hoffmann La Roche Inc. and Revlon Health Care Group. Dr. Dunton is a seasoned pharmaceutical executive with extensive Board-level experience. He has been Chairman and Director of EpiCept Corporation since January 5, 2012. He served as the Non-Executive Chairman of ActivBiotics Inc. from December 2005 to 2007. He has been a Director of Targacept Inc since October 2006. He has been an Independent Director of Oragenics Inc. since April 1, 2011. He has been a Director of Panacos Pharmaceuticals Inc since January 8, 2007. He has been a Director of Sancilio & Company, Inc. since July 2012. He has been an Independent Director of Palatin Technologies Inc. since June 22, 2011. He serves as a Member of the Advisory Board of Rosa Pharmaceuticals. He served as a Director of VWR International LLC since May 17, 2006. He served as a Director of VWR Funding Inc. since May 2006, Durata Therapeutics, Inc. (Formerly Vicuron Pharmaceuticals Inc.) from September 20, 2004 to 2005 and Adams Respiratory Therapeutics Inc. since November 08, 2006. Dr. Dunton served as a Director of MetaPhore Pharmaceuticals, Inc. He served as a Director of Medicinova Inc. from May 11, 2006 to January 28, 2011. He is a recipient of the prestigious Nellie Westerman Prize from the American Federation of Clinical Research for his work in medical ethics, specifically in the area of HIV research. He is a recognized leader in drug development and clinical research. His teaching appointments include Stanford University School of Medicine, Newark Beth Israel Medical Center and NYU Medical Center. He completed his Fellowship in Clinical Pharmacology at Cornell University/Medical College/New York Hospital. Dr. Dunton has M.D Degree from New York University School of Medicine in 1980 and completed his Post-graduate training in Internal Medicine at the New York University Medical Center/Bellevue Hospital VA Medical Center. He holds a BS in Biochemistry from State University School of New York at Buffalo.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
PANC:US	$0.01 USD	0.00

COMPETITOR COMPENSATION